Recently, Apetoh et al. has shown that patients with Toll-like receptor (TLR)-4 mutation do not mount a chemotherapy-primed anti-tumor immune response, whereas intact TLR-4 binds high mobility group box 1 (HMGB1), an early mediator of inflammation, to activate DCs [34]. The gene discussed is HMGB1; the disease is neoplasm.